Abzena, an integrated CDMO and CRO for complex biologics and bioconjugates, has expanded its early and late-phase analytical capabilities to include GMP cell-based potency assays at its Cambridge, UK and San Diego, CA development and manufacturing facilities. The expansion enhances the company’s bioassay offering.    GMP cell-based potency assays play an essential role in quantitatively measuring the biological activity of a biopharmaceutical, and the cytotoxicity of the payload of an Antibody...